Alpha-1-antichymotrypsin variant detected by PCR-single strand conformation polymorphism (PCR-SSCP) and direct
1Department of Molecular Life Science, Tokai University, School of Medicine, Kanagawa, Japan.
Human Genetics
|December 1, 1992
Summary
Researchers discovered a novel alpha-1-antichymotrypsin (ACT) variant with a two-base deletion at codon 391. This genetic mutation alters the downstream amino acid sequence, resulting in a peptide chain elongation.
Area of Science:
- Biochemistry
- Genetics
- Molecular Biology
Background:
- Alpha-1-antichymotrypsin (ACT) is a serine protease inhibitor.
- Genetic variations in ACT can impact protein function and associated diseases.
Purpose of the Study:
- To identify and characterize novel genetic variants of alpha-1-antichymotrypsin.
- To investigate the structural and potential functional consequences of identified mutations.
Main Methods:
- Polymerase chain reaction single strand conformation polymorphism (PCR-SSCP) was employed for mutation screening.
- Direct sequencing was utilized to confirm the identified genetic alteration.
Main Results:
- A new mutant ACT variant was identified.
- The mutation involves a deletion of two bases (AA) at codon 391.
- This deletion resulted in a frameshift, altering the downstream amino acid sequence and causing a 10-amino acid peptide chain elongation.
Conclusions:
- A novel deletion mutation in alpha-1-antichymotrypsin has been characterized.
- The identified variant (variant ACT) leads to significant structural changes in the protein due to peptide chain elongation.
- Further studies are warranted to determine the functional implications of this variant.
